TY - JOUR
T1 - New therapeutic landscape of NNRTIs for treatment of HIV
T2 - A look at recent data
AU - Jayaweera, Dushyantha
AU - Dilanchian, Paula
N1 - Funding Information:
Editorial and writing support was funded by Boehringer Ingelheim. D Jayawerra has received support as a speaker for Janssen, BMS, Merck, Gilead (inactive since 1/1/2012), has received research support from Vertex, Gilead, ViiV Healthcare, Bristol Meyers Squibb (currently active), and has consulted for Gilead and Janssen (inactive since 6-1-12). P Dilanchian declares no conflicts of interest. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development and have approved the final version of this review that reflects the authors’ interpretation and conclusions. Medical writing assistance was supported financially by Boehringer Ingelheim Envision Scientific Solutions during the preparation of this review. Boehringer Ingelheim was given the opportunity to check the data used in the manuscript for factual accuracy only.
PY - 2012/12
Y1 - 2012/12
N2 - Introduction: A key Objective with highly active antiretroviral therapy for the treatment of HIV infection has been the optimization of antiretroviral drug combinations for individual patients. Areas covered: Overall, non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (in combination with two nucleoside reverse transcriptase inhibitors (NRTIs)) have become mainstays for initial ARV regimens. Early NNRTIs, efavirenz and nevirapine, are similarly efficacious, but differ according to their toxicity profiles. Newer NNRTIs, rilpivirine and etravirine are also efficacious. Etravirine was designed to overcome common first-line NNRTI resistance mutations, and serves as a second line agent. Expert opinion: As a class, NNRTIs are key components of ARV regimens. Currently, there are 3 NNRTIs that may be used in first-line regimens, and one in second-line regimens. ARV regimen optimization depends on matching individual drug efficacy, safety, resistance, and toxicity profiles to particular patients. Once-daily dosing options are essential to treatment simplification strategies, which have been shown to enhance regimen compliance and durabiltiy. These are especially important due to the low genetic barrier to resistance generally associated with NNRTIs. As newer drugs are introduced, especially as part of once-daily, single-tablet regimens, this will expand the number of convenient and efficacious treatment options available.
AB - Introduction: A key Objective with highly active antiretroviral therapy for the treatment of HIV infection has been the optimization of antiretroviral drug combinations for individual patients. Areas covered: Overall, non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (in combination with two nucleoside reverse transcriptase inhibitors (NRTIs)) have become mainstays for initial ARV regimens. Early NNRTIs, efavirenz and nevirapine, are similarly efficacious, but differ according to their toxicity profiles. Newer NNRTIs, rilpivirine and etravirine are also efficacious. Etravirine was designed to overcome common first-line NNRTI resistance mutations, and serves as a second line agent. Expert opinion: As a class, NNRTIs are key components of ARV regimens. Currently, there are 3 NNRTIs that may be used in first-line regimens, and one in second-line regimens. ARV regimen optimization depends on matching individual drug efficacy, safety, resistance, and toxicity profiles to particular patients. Once-daily dosing options are essential to treatment simplification strategies, which have been shown to enhance regimen compliance and durabiltiy. These are especially important due to the low genetic barrier to resistance generally associated with NNRTIs. As newer drugs are introduced, especially as part of once-daily, single-tablet regimens, this will expand the number of convenient and efficacious treatment options available.
KW - AIDS
KW - Clinical trials
KW - Drugs
KW - HIV
KW - Nevirapine
KW - NNRTI
KW - Review
KW - Therapy
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84870202766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870202766&partnerID=8YFLogxK
U2 - 10.1517/14656566.2012.742506
DO - 10.1517/14656566.2012.742506
M3 - Review article
C2 - 23176566
AN - SCOPUS:84870202766
VL - 13
SP - 2601
EP - 2612
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 18
ER -